K
Kristin E. Burke
Researcher at Harvard University
Publications - 62
Citations - 3092
Kristin E. Burke is an academic researcher from Harvard University. The author has contributed to research in topics: Inflammatory bowel disease & Medicine. The author has an hindex of 17, co-authored 48 publications receiving 2276 citations. Previous affiliations of Kristin E. Burke include Beth Israel Deaconess Medical Center & Millennium Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Teresa A. Soucy,Peter G. Smith,Michael Milhollen,Allison Berger,James M. Gavin,Sharmila Adhikari,James E. Brownell,Kristin E. Burke,Cardin David P,Stephen Critchley,Courtney Cullis,Amanda Doucette,James J. Garnsey,Gaulin Jeffrey L,Rachel E. Gershman,Anna R. Lublinsky,Alice McDonald,Hirotake Mizutani,Usha Narayanan,Edward J. Olhava,Stephane Peluso,Mansoureh Rezaei,Michael D. Sintchak,Tina Talreja,Michael P. Thomas,Tary Traore,Stepan Vyskocil,Jie Yu,Julie Zhang,Lawrence R. Dick,Christopher F. Claiborne,Mark Rolfe,Joseph B. Bolen,Steven P. Langston +33 more
TL;DR: MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumour cells by a new mechanism of action, the deregulation of S-phase DNA synthesis, suggesting that NAE inhibitors may hold promise for the treatment of cancer.
Journal ArticleDOI
Clostridium difficile infection: a worldwide disease.
TL;DR: The epidemiology, microbiology, pathophysiology, and clinical management of C. difficile are reviewed to determine whether and how to implement appropriate infection control practices.
Journal ArticleDOI
Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs
Susannah Hewitt,Ailin Bai,Dyane Bailey,Kana Ichikawa,John Zielinski,Russell Karp,Ameya Apte,Kristen Arnold,Sima Zacharek,Maria S. Iliou,Khushbu Bhatt,Maija Garnaas,Faith Musenge,Ashley Davis,Nikhil Khatwani,Stephen V. Su,Graham MacLean,Samuel J. Farlow,Kristin E. Burke,Joshua Frederick +19 more
TL;DR: Direct intratumoral delivery of messenger RNAs encoding inflammatory cytokines and T cell costimulator OX40L produced robust anticancer responses in a broad range of tumor microenvironments, suggesting translatability of immunomodulatory activity to human patients.
Journal ArticleDOI
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
John Sarantopoulos,Geoffrey I. Shapiro,Roger B. Cohen,Jeffrey W. Clark,John S. Kauh,Glen J. Weiss,James M. Cleary,Devalingam Mahalingam,Michael D. Pickard,Hélène M. Faessel,Allison Berger,Kristin E. Burke,George Mulligan,Bruce J. Dezube,R. Donald Harvey +14 more
TL;DR: Pevonedistat was generally well tolerated on a day 1, 3, 5 schedule every 3 weeks with an MTD between 50 mg/m2 and 67 mg/ m2, and Pharmacodynamic studies demonstrated that pevonedistsat inhibited NAE in tumors.
Journal ArticleDOI
Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates†
TL;DR: These data demonstrate that blocking the &agr;4&bgr;7 integrin exclusively yields gut‐selective antiinflammatory activity in primates.